OncoSec Medical (NASDAQ:ONCS) receives $25 price target and Buy rating from leading analyst


OncoSec Medical Inc

Expert analysts at HC Wainright has Buy rating on OncoSec Medical Inc (OTC:ONCS). The firm has started coverage in an analyst report made public on Tuesday morning. HC Wainright's target would suggest upside of 246.74% from the company's last stock close.

The new coverage is welcomed by equity traders, as OTC:ONCS is currently trading 3.59% higher at $7.21 as of 07:56 New York time. OncoSec Medical Inc shares have decreased -34.45% over the last 200 days, while the Standard & Poor's 500 index has added 6.27% in the same time.

Out of 3 analysts covering OncoSec Medical Inc, 3 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $60 and the lowest is $25 according to Thomson/First Call. The 12-month mean target is $41.67, which means upside potential of 477.95% over the current price.

OTC:ONCS Price Chart & Trend
The stock price of OncoSec Medical Inc has decreased 34.45% over the last 200 days, and is in strong down trend. In the last 50 and 100 days, OncoSec Medical Inc is up 9.24% and down 7.56%, respectively. Our stocks momentum model is shown on the price chart below





Disclaimer

All statements and opinions expressed herein are those of the editors and staff of Avenaddy, Inc. and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell any of the securities mentioned. Avenaddy Inc, its principals or employees are not registered investment advisors or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this newsletter. Investing in securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission at http://www.sec.gov and/or the National Association of Securities Dealers at http://www.finra.org. We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The Avenaddy Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The newsletter sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinion about the company and the trading market for their securities. Principals of the newsletter may also purchase or sell securities of the companies in the open market from time to time. Avenaddy, Inc. in conjunction with Mobius Bio has received compensation of five thousand dollars cash from OncoSec for the distribution of this newsletter, and should be considered in making an investment decision regarding companies mentioned in this newsletter. The information found in this newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of Avenaddy, Inc.

Email Marketing